Lilly launches Lormalzi® (Donanemab), first and only once-monthly amyloid plaque-targeting therapy for the treatment of early symptomatic Alzheimer’s Disease in India
Kolkata, 15 May, 2026 – Eli Lilly and Company (India) Pvt. Ltd. today announced the launch of Lormalzi® (donanemab, 350 mg/20 mL IV vial) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer’s disease with mild cognitive impairment or those in the mild dementia stage of disease.¹˒² Lormalzi® is the first and only once‑monthly…